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Stroke, a major cause of mortality and disability, occurs in >610 000 people and accounts for $38.6 billion in 
direct and indirect medical costs annually in the United 
States.1 Opportunity for improvement in stroke prevention 
and stroke care is broadly acknowledged.1,2 Significant stroke 
burden and opportunity for improvement also exists in the 
Veterans Affairs (VA) health system. The VA Stroke Quality 
Enhancement Research Initiative (QUERI) was created to 
translate evidence into system-wide practice to reduce stroke 
risk, improve patient care, and to help Veterans reach the best 
possible outcomes poststroke.3
To prioritize their efforts, the Stroke QUERI executive com-
mittee recognized the need for quantitative impact estimates 
of investment alternatives in research and implementation to 
reduce stroke burden. Given the Stroke QUERI’s extensive 
charge, including primary prevention, acute care and rehabili-
tation, secondary prevention, and the need to accommodate a 
wide range of stakeholder involvement, the executive commit-
tee sought a systematic, analytic approach to strategic planning.
In close collaboration with stroke experts and QUERI deci-
sion-makers, we built and analyzed a population-level System 
Dynamics stroke model for Veterans to estimate the relative 
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impact of 15 intervention scenarios for supporting decision-
making. Given the need to guide research and practice to 
improve stroke outcomes VA-wide, the project was intended 
to focus on classes of interventions of particular importance to 
VA leadership. Through literature review and engagement of 
a diverse team of stroke experts, we sought to ground simu-
lated intervention scenarios in current practice in VA facilities, 
and plausible changes based on understanding of the VA con-
text. We examined the comparative impact of proposed inter-
vention approaches on population-level health outcomes, as 
well as their relative efficiency. In addition, we evaluated the 
robustness of results given potential data uncertainties.
Methods
Decision Model Overview
To better understand trade-offs between alternate stroke care im-
provement targets, we built a population-level System Dynamics 
stroke model for the US VA enrollee population. Throughout the 
process of model development, we engaged with experts both within 
VA and more broadly to integrate their understanding of stroke and 
stroke care. Vensim DSS 5.114 was used for model construction, pa-
rameterization, calibration, and evaluation. We initiated the model in 
2010 with a population of 4.14 million VA users, defined as Veteran 
enrollees who used VA primary care service in the past 12 months. 
This subpopulation of enrollees, considered reachable by VA-based 
intervention, comprised 48% of all Veteran enrollees (based on 
2007 data from Veterans Administration Desert Pacific Healthcare 
Network/Veteran Integrated Service Network 22 databases). The 
model introduced a fraction of the VA enrollee nonuser population 
each year, who become VA users after an incident transient ischemic 
attack (TIA) or stroke.
Accounting for heterogeneous stroke or TIA risk, the model strati-
fied VA users into 11 mutually exclusive stocks (depicted as solid 
rectangles in Figure 1) representing individuals with similar natural 
history and response to treatment (eg, history of recent diagnosed 
TIA). Veteran users without prior TIA or stroke were segmented by 
stroke risk factors: age (<45, 45–64, 65–75, and >75), hypertension, 
and systolic blood pressure (<140, 140–159, and >160 mm Hg), atrial 
fibrillation (AF), diabetes mellitus type 2, smoking, and cardiovas-
cular disease (CVD). The post-TIA population was disaggregated by 
diagnosis (diagnosed versus undiagnosed) and time since last TIA 
event; the poststroke population was categorized by time since most 
recent stroke and functional independence via modified Rankin Scale.
The System Dynamics model simulated the transitions between 
health states (stocks) via flows over time. Typical of SD models, move-
ments among health states were governed by processes with multiple 
influences, nonlinearity, accumulation, delay, and feedback.5 Input 
parameters (omitted from Figure 1 for simplification) include time 
delays, constants, rates, and time series inputs. More information on 
model assumptions can be found at http://vastrokemodel.weebly.com.
Data Sources
The projections of VA user demographics were based on the Veteran 
Population Projection Model6 and Decision Support Services Veteran en-
rollee data. Current levels of care in the VA were largely based on a study 
conducted by the Veterans Health Administration Office of Quality and 
Performance and Stroke QUERI during fiscal year 2007.7 A Framingham-
based risk calculator was used to determine relative stroke rates as the 
pre-event population changed with time either based on exogenous fac-
tors or through intervention.8 To achieve this, the pre-event population 
was stratified into 256 risk groups reflecting relevant combinations of 
key stroke risk factors; the prevalence of each risk factor and risk factor 
combination was based on Veteran Integrated Service Network 22 data 
but cross-checked against national single-factor prevalence estimates.6,8,9 
The risk calculator used was selected as the best match to available risk 
data and specific prevention interventions considered in the model. The 
distribution of poststroke functional status was estimated based on VA 
Functional Status Outcomes Database data,10–12 though estimates from 
the literature were used in sensitivity analysis.13 Age-specific nonstroke 
death rates were derived from the US Census Life Tables. In the absence 
of data, literature review with VA source preference14–16 was conducted 
to inform assumptions. For example, while national sources were com-
pared, the initial prevalence of TIA and stroke were estimated from a 
study on large administrative VA medical databases.14
Intervention Scenarios
We worked with Stroke QUERI decision-makers and additional stake-
holders to develop 15 distinct intervention scenarios representing the 
Figure 1. Depicted in the diagram are the 
stocks (solid rectangles) and flows (arrows), 
which capture the states and changes in 
health status of the Veteran enrollee popu-
lation over time. The dashed rectangles 
show the descriptive segmentation of the 
Veteran population based on history of 
transient ischemic attack (TIA) or stroke. 
The flows in the model manipulate the tran-
sitions between stocks which shift individu-
als between states over time and ultimately 
affect modeled outcome variables. Veter-
ans Affairs (VA) users without prior TIA or 
stroke are not tracked as a stock but rather 
a flow into indicated stocks. mRS indicates 
modified Rankin Scale.
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policy decision space (Table 1). Scenarios were organized into 3 cat-
egories: primary prevention, secondary prevention, and acute care/
rehabilitation. Each intervention scenario was defined based on evi-
dence about specific interventions within the categories, current VA 
levels of care (what proportion of eligible individuals are receiving 
the intervention), projected level of care with plausible effort, and 
expected intervention effectiveness.
Sensitivity Analysis, Model Calibration, and 
Uncertainty Analysis
Given the breadth of the model and gaps in VA data, it was important 
to conduct a rigorous sensitivity analysis to identify key uncertain 
parameters, model calibration to estimate these parameter values 
given additional data, and uncertainty analysis to assess robustness 
of findings given existing uncertainty.29 To reduce the number of pa-
rameters that needed to be estimated, we applied the Morris method30 
to identify the subset of parameters to which either model outputs or 
calibration criteria (ie, the calculated difference between additional 
data points and their simulated equivalent) were most sensitive (ie, 
contributed the most to variability in each). Next, those parameters 
to which calibration criteria were most sensitive were estimated (ie, 
calibrated) using generalized likelihood uncertainty estimation.31 
Calibration was performed to produce >400 000 replications of the 
model. We selected the 1000 best-fitting parameter sets to serve as al-
ternate baselines for uncertainty analysis. Finally, we conducted mul-
tivariate probabilistic sensitivity analysis to account for uncertainties 
in the 15 intervention scenarios’ effect sizes as well as in additional 
noncalibrated model inputs parameter values to which model outputs 
were sensitive. In total, 10 000 distinct model replications per inter-
vention scenario were simulated to represent uncertainty in model 
input parameter values.
Outcomes
Each intervention was simulated sequentially in each replication of 
the model, and results were calculated by taking the difference in 
cumulative quality-adjusted life years (QALYs), incident strokes, 
and stroke fatalities during a 20-year time period. While these results 
inform relative population-level impacts of each intervention, they 
do not capture differences in resources required to achieve these im-
pacts. As a clinically and operationally relevant surrogate for actual 
resource utilization and efficiency, we calculated the number-needed-
to-treat (NNT) to achieve a 1-unit change in QALY during a 20-year 
period. A discount rate of 3% was applied to all outcomes.
Because the simulated outcomes were highly skewed, we reported 
the median of each outcome across the 10 000 replications, with 95% 
uncertainty bounds for each intervention. Uncertainty bounds were de-
rived from the cumulative distribution function of each output predic-
tion, rescaling based on the likelihood estimates of the 1000 best-fitting 
baselines. In addition, we applied Mann–Whitney U test32 (2-tailed), a 
nonparametric test, to assess the statistical significance of differences 
in NNT per QALY gained across all possible pairs of intervention sce-
narios across replications. We tested a set of null hypotheses that there 
is no difference between each pair of intervention scenarios.
Results
The Morris method30 reduced the complexity of the model 
calibration by identifying 36 parameters (out of 60) to which 
calibration criteria or model outputs were most sensitive. It 
is worth noting that the most influential parameter across all 
the outputs is the stroke rate per thousand in the pre-event VA 
user population per year. Additional data collection and rigor-
ous estimates of it could dramatically reduce uncertainty in 
projected stroke outcomes.
Table 2 presents simulated outputs across the 15 interven-
tion scenarios in a descending order with respect to QALYs 
gained for 20 years. Improving hypertension control for all 
VA users from baseline (73%) to a plausibly achievable level 
(between 87% and 95%) yielded the largest benefits in 20-year 
QALYs gained, strokes prevented, and stroke fatalities pre-
vented. Carotid endarterectomy for individuals with prior 
stroke had the lowest improvement in QALYs. Because of the 
small number of eligible individuals relative to other inter-
ventions, thrombolytic therapy with tissue-type plasminogen 
activator for acute stroke had a relatively small impact at the 
population level but was the most efficient strategy in terms 
of NNT per QALY gained (3.1). Increasing eligible strokes 
receiving rehabilitation service from baseline (30%) to 60% 
ranked second in terms of NNT per QALY gained (3.9). At 
current tissue-type plasminogen activator administration lev-
els, system-wide effort to increase the fraction of individuals 
arriving at the hospital within 60 minutes of stroke symptom 
onset was the least efficient strategy evaluated.
A box plot illustrating the expected NNT per QALY gained 
and estimated uncertainty, grouped by intervention category, 
is shown in Figure 2. Within each category, interventions 
are ordered from lowest NNT per QALY to highest. Though 
hypertension control for all VA users yields the greatest pop-
ulation-level benefit among primary prevention interventions, 
it is the least efficient in this category. More efficient were: 
targeted primary prevention focusing on specific high-risk 
groups including VA users with severe hypertension, diabe-
tes mellitus, prior CVD, or AF, as well as targeted hyperten-
sion and anticoagulation treatment for VA users with prior 
CVD and AF. Among secondary prevention interventions, 
the top 3 efficient interventions on NNT per QALY gained 
are management of recently diagnosed TIA (6.0), accurate 
and timely TIA diagnosis (9.0), and carotid endarterectomy 
post-TIA (9.4). Comparing intervention impacts across rep-
lications, the Mann–Whitney U test revealed that all pairs of 
these 15 interventions were statistically significantly differ-
ent from each other in terms of NNT per QALY gained at a 
significance level of P<0.001.
Discussion
In this article, we describe a computer model of stroke inci-
dence and outcomes in the VA population and present analy-
ses offering the Stroke QUERI a systematic foundation for 
understanding the impact of implementing alternate strategies 
for stroke prevention and treatment under consideration. From 
this project, we learned that several interventions have both 
large cumulative benefits to the Veteran population and are 
also relatively efficient in terms of NNT per QALY gained, 
including targeting individuals with a history of CVD for 
treatment of hypertension and AF and rehabilitation after 
acute stroke. This finding is being used by the Stroke QUERI 
to focus research and implementation efforts.
This study also revealed that broad-based prevention, such 
as improving hypertension management for all Veterans, 
was powerful in terms of cumulative benefits to the popu-
lation, though not always as efficient as other intervention 
approaches because larger numbers of individuals must 
be treated for each unit of benefit. For example, consider-
ing QALY gains in Table 2, targeted prevention focused on 
hypertension and anticoagulation for individuals with AF 
among the subset of VA users with prior CVD achieves 78% 
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Table 1. Description of Current and Projected Levels of Care Under 15 Stroke Intervention Scenarios Simulated in the Model
Description of Intervention 
Scenarios
Target Subpopulation 
Among VA Users Current Level of Care*
Projected Achievable  
Level of Care Estimated Effect Size†
Pre-event primary prevention
Improve hypertension 
control for all VA users with 
SBP >140 mm Hg
All pre-event users with 
140 mm Hg<SBP<160 
mm Hg
73% with SBP <140 mm Hg 91% with SBP <140 
mm Hg (87%–95%)
19% stroke RRR for movement from  
140 mm Hg<SBP<160 mm Hg to SBP  
<140 mm Hg and 31% for movement  
from >160 mm Hg to <140 mm Hg17
Improve hypertension  
control for VA users with  
SBP >160 mm Hg
All pre-event users with 
SBP >160 mm Hg
4% with SBP >160 mm Hg 2% with SBP >160 mm Hg 
(1.5%–2.5%)
31% RRR of stroke17
Improve hypertension 
control for VA users with 
DM
All pre-event users with 
DM and HTN
90% with SBP <140 mm Hg 97% with SBP <140 
mm Hg (95%–98%)
18% stroke RRR for movement from  
140 mm Hg<SBP<160 mm Hg to SBP  
<140 mm Hg and 31% for movement from 
>160 mm Hg to <140 mm Hg17
Improve ischemic stroke 
prevention for all eligible VA 
users with AF (antiplatelet/ 
anticoagulation therapy)
All pre-event users with AF 34% with TTR >60% 60% (40%–80%) 66% stroke RRR for anticoagulation18,19
Improve hypertension 
control and management of 
AF for VA users with prior 
cardiovascular disease 
All pre-event users with 
CVD HTN and AF
No AF: 73% SBP <140 
mm Hg
AF: 78% SBP <140 mm Hg 
and 34% with TTR >60%
No AF: 89% SBP <140 
mm Hg
(85%–93%)
AF: 91% SBP <140 mm Hg
(88%–94%)
60% TTR >60%  
(40%–80%)
19% stroke RRR for movement from  
140 mm Hg<SBP<160 mm Hg to SBP  
<140 mm Hg and 31% for movement from 
>160 mm Hg to <140 mm Hg17 66% stroke 
RRR for anticoagulation18,19
Secondary prevention
Improve accuracy/ 
timeliness of TIA diagnosis 
in VA users by increasing 
awareness/symptom 
recognition 
All incident TIAs  
among VA users
71% of TIAs 
diagnosed‡(range 70%– 
80%)
81% (81%–85%) Greatest stroke risk in first week after TIA; 
diagnosed can receive prevention
Improve the immediate 
management of TIA through 
expedited evaluation and 
risk factor management
All diagnosed TIAs 39% managed well‡
(range 39%–53%)
80% (61.3%–83.8%) 40% reduction in risk of stroke for  
highest risk period‡ (90 days post-TIA;  
range 40%–72%)20
Improve the rate of CEA for 
eligible individuals post-TIA
All eligible VA users  
post-diagnosis of TIAs
15% of diagnosed TIA 
eligible; 35% of these 
receive CEA
60% (40%–75%) Average of 37.5% RRR of recurrent  
TIA or stroke21
Increase % of patients with 
stroke receiving guideline 
concordant stroke care for 
secondary prevention
All incident strokes  
among VA users
30%‡ 60%(50%–70%) 40% reduction in risk of stroke for next  
90 d‡ (range 40%–72%)20
Improve the rate of CEA for 
eligible individuals following 
acute ischemic stroke
All eligible VA users 
poststroke
15% of strokes eligible, of 
these 35% receive CEA
60% (40%–75%) Average of 37.5% RRR of  
recurrent stroke21
Acute treatment/rehabilitation
Increase % of acute stroke 
ED arrival within 60 min of 
symptom onset
All incident strokes  
among VA users
18% of acute strokes ED 
arrival within 60 min
35% (27.5%–53.8%) Increases percentage of individuals  
eligible for tPA22,23
Improve the use of 
thrombolytic therapy with 
tPA within the VA health 
care system
Incident strokes eligible  
for tPA among VA users
33% of veterans arriving  
on time are medically 
eligible for tPA; of these, 
11% of receive tPA
44% (18%–48%) 36% RRR in functional loss for tPA within  
3 h and 5% RRR of death during the acute 
period (corresponding to a 0.6 percentage 
point absolute risk reduction)24,25
Increase the % of 
ischemic stroke patients 
receiving proper deep 
venous thromboembolism 
prophylaxis
All incident strokes  
among VA users
79% 91% (81%–94%) 12.5% RRR of death during the acute  
period (corresponding to a 1.4% point 
absolute risk reduction)26
(Continued)
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of the gains that improving hypertension control for all users 
achieves. Echoing the guidelines for primary prevention of 
stroke,33 our study suggested that more efficient primary pre-
vention should target high-risk subgroups of Veterans either 
with more severe condition (eg, severe hypertension with sys-
tolic blood pressure >160 mm Hg) or with elevated risk in the 
presence of multiple stroke risk factors (eg, prior history of 
CVD and hypertension).
A crucial feature of this exercise is that it was performed 
to address the VA decision context and results may differ in 
non-VA populations. For example, the efficacy of tissue-type 
plasminogen activator will be dependent on local context, 
such as the proportion of people with stroke arriving soon 
after symptom onset and baseline rates of tissue-type plas-
minogen activator use. Results also depend on the framing of 
key questions, for example if acute interventions were con-
solidated under a stroke unit.
This work is based on available data; as such, one limita-
tion is that several of the model inputs are uncertain. However, 
guided by sensitivity analysis, we identified where uncertainty 
in inputs most affected outputs and focused our literature 
review, data analysis, and consultation with the Stroke QUERI 
advisory committee on those inputs. We addressed remaining 
uncertainties through rigorous probabilistic sensitivity analy-
sis and demonstrated that the strategic conclusions presented 
here are robust to these uncertainties.
A second limitation is that costs are not included directly, 
because of the complexity of cost estimation in this broad 
model and the variability in costs across facilities; instead 
we used the surrogate of NNT as an indicator of efficiency. 
Table 2.  Median and 95% Uncertainty Bounds for Key Stroke Outcomes for Each Stroke Intervention Scenario Compared 
With Current Level of Care for 20 Years
QALYs Gained Strokes Prevented Stroke Fatalities Prevented NNT per QALY Gained
Hypertension control for all VA usersPP 35 517 (27 302, 48 540) 20 940 (15 637, 29 413) 2440 (1547, 3919) 11.8 (9, 14.2)
Hypertension control and anticoagulation 
for those with prior CVDPP
27 856 (19 493, 40 131) 16 479 (11 290, 24 368) 1911 (1123, 3208) 5.1 (3.6, 7)
Hypertension control for diabeticsPP 23 100 (16 990, 32 481) 13 688 (9756, 19 805) 1585 (986, 2609) 9.2 (7.1, 11)
RehabilitationTR/R 18 974 (12 845, 27 872) 210 (–71, 664) 73 (15, 164) 3.9 (3, 4.8)
Management of recently diagnosed TIASP 10 838 (6391, 17 304) 6382 (4043, 9665) 727 (405, 1243) 6.0 (4.5, 7.5)
Anticoagulation for all with AFPP 9568 (2553, 18 205) 5643 (1521, 11 096) 642 (163, 1422) 8.1 (6.2, 9.7)
Comprehensive poststroke managementSP 6315 (2970, 10 985) 10 283 (6095, 15 879) 1340 (743, 2246) 17.0 (12.3, 26.4)
Dysphagia screeningTR/R 2574 (1239, 4994) –119 (–207, –63) 645 (344, 1150) 67.8 (45.1, 110.4)
Hypertension control for VA users with 
SBP >160PP
2351 (1762, 3221) 1385 (997, 1963) 161 (100, 260) 5.7 (3.7, 7.7)
DVT prophylaxisTR/R 2001 (565, 4690) –94 (–193, –28) 509 (151, 1078) 16.3 (10.8, 26.5)
Thrombolytic therapyTR/R 1180 (405, 2213) 0 (–11, 27) 31 (10, 65) 3.1 (1.1, 4.4)
CEA for post-TIASP 748 (194, 1434) 449 (116, 801) 51 (13, 106) 9.4 (7.4, 11.4)
Time to hospital within 60 min of 
symptoms onsetTR/R
733 (342, 1270) 0 (–6, 16) 19 (9, 37) 122.3 (84.4, 158.3)
Accuracy/timeliness of TIA diagnosisSP 723 (190, 2555) 440 (121, 1545) 51 (14, 207) 9.0 (7.3, 11.3)
CEA for poststrokeSP 344 (87, 747) 655 (170, 1222) 84 (22, 170) 35.6 (28.2, 55.5)
A 3% discount rate is used in all calculations. AF indicates atrial fibrillation; CEA, carotid endarterectomy; CVD, cardiovascular disease; DVT, deep vein 
thrombosis; NNT, number-needed-to-treat; PP, primary prevention; QALY, quality-adjusted life year; SBP, systolic blood pressure (measured in mm Hg); SP, 
secondary prevention; TIA, transient ischemic attack; TR/R, treatment/rehabilitation; and VA, Veterans Affairs.
Table 1. Continued
Description of Intervention 
Scenarios
Target Subpopulation 
Among VA Users Current Level of Care*
Projected Achievable  
Level of Care Estimated Effect Size†
Increase the % of acute 
ischemic patients with 
stroke receiving dysphagia 
screening on admission
All incident strokes  
among VA users
23% 84% (50%–88%) 3.3% RRR of death within the  
acute period27
Increase % of eligible 
patients with stroke receiving 
guideline concordant 
rehabilitation services
All eligible VA users 
poststroke 
30% 60% (55%–73%) 35% reduction in risk of ending in mRS  
4–5 and mRS 2–3, ending in mRS 2–3  
and mRS 0–1, respectively28
Fifteen stroke intervention scenarios are defined, with each including a target subpopulation, current and projected level of care, and estimated effectiveness of 
the intervention. AF indicates atrial fibrillation; CEA, carotid endarterectomy; CVD, cardiovascular disease; DM, diabetes mellitus; ED, emergency department; HTN, 
hypertension; mRS, modified Rankin Scale; RRR, relative risk reduction; SBP, systolic blood pressure (measured in mm Hg); TIA, transient ischemic attack; tPA, tissue-
type plasminogen activator; TTR, time in therapeutic range; and VA, Veterans Affairs.
*Baseline (the comparator and current level of care); †workgroup consensus; and ‡calibrated within the model.
 by guest on D
ecem
ber 23, 2016
http://stroke.ahajournals.org/
D
ow
nloaded from
 
Hassmiller Lich et al  Simulation-Based Strategic Planning in the VA   2083
This allows general comparisons of similar interventions (eg, 
lifetime medication and clinical management for prevention) 
but is less relevant in comparing across the 3 broad interven-
tion categories. We found the NNT analysis a useful refer-
ence point for Stroke QUERI discussion of the relative cost, 
feasibility, and sustainability of specific interventions; NNT 
provided decision-makers a way to visualize the number of 
people who would need to receive the intervention in order to 
achieve 1 QALY.
A third limitation is that the benefits of prevention are 
underestimated in this study. For instance, hypertension con-
trol not only reduces the risk of stroke, but also lowers the 
risk of myocardial infarction, heart failure, and chronic kid-
ney disease whose benefits are not explicitly included in our 
results given the focus on stroke. Accounting for this second-
ary effect would only reinforce the estimated cumulative ben-
efits of prevention.
The SD stroke model presented here serves as a tool for 
policy makers to focus research on crucial points of uncer-
tainty to improve decision-making.34 This framework has 
been used by the VA Stroke QUERI in discussions about 
how to move forward in strategic planning and goal devel-
opment to improve the quality of stroke care in the VA sys-
tem.35 In response to results of the model, the Stroke QUERI 
has expanded its allocation of research and implementation 
on prevention, including new efforts to improve secondary 
prevention among Veterans post-TIA or stroke, and improved 
integration with other QUERIs addressing hypertension in 
high-risk individuals. The model has potential to be applied 
to other contexts, particularly other managed health systems; 
the structure of the model can be adapted, accounting for local 
data, resources, and constraints. Furthermore, it provides an 
example of how modeling can be applied to address clinical 
and public health policy problems to promote positive action.
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gained, excluding outliers. Outliers are depicted by solid circles. The vertical axis is on a logarithmic scale. *P<0.001 when Mann–Whitney 
U test is applied to examine whether NNT per QALY gained for each intervention is significantly different from each other intervention. AF 
indicates atrial fibrillation; CEA, carotid endarterectomy; CVD, cardiovascular disease; SBP, systolic blood pressure (measured in mm Hg); 
TIA, transient ischemic attack; tPA, tissue-type plasminogen activator; and VA, Veterans Affairs.
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